Neurosurgery Customer from Germany Orders Nexstim NBS System 5
2024年4月26日 - 9:00PM
Neurosurgery Customer from Germany Orders Nexstim NBS System 5
Press release, Helsinki, 26 April 2024 at 3 PM
(EEST)
Neurosurgery Customer from Germany
Orders Nexstim NBS System 5
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")
has received an order for a new NBS System 5 from an existing
customer hospital in Germany. The system will be used in
neurosurgery.
The Nexstim Navigated Brain Stimulation (NBS)
System 5 is indicated for non-invasive mapping of the primary motor
cortex of the brain to its cortical gyrus and localization of
cortical areas that do not contain essential speech function. The
information gained from the mapping may be used in pre-procedural
planning.
Mikko Karvinen, CEO of Nexstim, comments: “Our
diagnostics system offers a unique possibility for neurosurgeons to
receive crucial information about the location of vital functional
areas before a surgery. We are happy to have one of our existing
customers in Germany order a new NBS 5 system. This is a clear sign
of the commitment that the Nexstim team has in maintaining
long-term customer relationships in this important market, and of
the real difference that our products are making in the everyday
work of neurosurgeons and other medical professionals.”
Further information is available on the
website www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO +358 50 326
4101 mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for presurgical mapping of the speech and motor cortices
of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Press release_EU order_26042024_FINAL